United Kingdom

People: Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

22 Jul 2019
Change (% chg)

$0.21 (+0.94%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Steensberg, Adam 

Mr. Adam Steensberg, M.D. has been Executive Vice President, Chief Medical and Development Officer (CMDO) at Zealand Pharma A/S since 2017. He no longer serves as Interim Chief Executive Officer of the Company effective as of April 22, 2019. He has held the position since March 1, 2019. He has previously been Senior Vice President and Chief Medical and Development Officer at Zealand Pharma A/S since March 19, 2015. Mr. Adam Steensberg joined Zealand in 2010 as Head of Clinical Development. Since 2011 he has been leading all development activities. Prior to joining Zealand, Adam has led several clinical research teams as medical director at Novo Nordisk A/S, and he has experience as clinician from the University hospital of Copenhagen. He has served as medical and scientific advisor within endocrinology, cardiology, gastroenterology, and rheumatology. He has experience with leading regulatory strategies and has been instrumental in implementing a patient-centric discovery and development process at Zealand. Adam has published more than 45 peer-reviewed scientific papers in international journals. Adam holds a Medical Doctor degree followed by a Doctor of Medical Sciences (DMSc/ dr.med) from the University of Copenhagen, Denmark and an MBA from IMD, Switzerland.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --